Loading...

Please wait while we retrieve your documents

CONFERENCE / INDJCPR Conference

Research Article

Paper Title (18 Bold)

Author1 Author2

First Author1, Second Author2 (12) 1,2Department, College/ University Name, Country Name (10 Italic)

Published Online: December 2025

Pages: 01-03

Cite this article

↗ https://www.doi.org/10.59256/indjcpr.20260404004
View PDF check update

Abstract

Analgesia, one of the components of triad of anaesthesia, has now extended to relief of postoperative pain, chronic pain and cancer pain. The spinal cord has taken the center stage in analgesia practice and Spinal anaesthesia is the commonly used technique for lower limb surgeries as it is easy to administer, economical and causes less hemodynamic variation than general anaesthesia. Hence different additives can be used to increase the duration of postoperative analgesia. Since there are no studies comparing Buprenorphine and Nalbuphine, we have selected this study to evaluate the effect of intrathecal Bupivacaine with Buprenorphine compared with Nalbuphine for postoperative analgesia.

Citations

First Author1, Second Author2 ,Department, College/ University Name, Country Name (10 Italic)

Licensing

© 2026 The Author(s). Published by Fifth Dimension Research Publication.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( http://creativecommons.org/licenses/by/4.0/ ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The terms on which this article has been published allow the posting of the Accepted Manuscript in a repository by the author(s) or with their consent.

Article Metrics

154
Views
0
Citations
PlumX Metrics PlumX Metrics
Dimension

References

  • [1]. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (AdultTreatment Panel III) Third report of the national cholesterol education (8) [2]. program (NCEP) expert panel on detection, evaluation, and treatment of highblood cholesterol in adults (adult treatment panel III) finalreport. Circulation. 2002;106(25, article 3143). [3]. Bener A, Zirie M, Janahi IM, Al-Hamaq AOAA, Musallam M, Wareham NJ.Prevalence of diagnosed and undiagnosed diabetes mellitus and its risk factorsin a population-based study of Qatar. Diabetes Research and Clinical Practice. 2009;84(1):99–106. [4]. Bener A, Zirie M, Musallam M, Khader YS, Al-Hamaq AOAA. Prevalence ofmetabolic syndrome according to adult treatment panel III and internationaldiabetes federation criteria: a population-based study. Metabolic Syndrome [5]. and Related Disorders. 2009;7(3):221–230 [6]. Bener A, Dafeeah E, Ghuloum S, Al-HamaqAOAA.Association between psychological distress and gastrointestinal symptoms in type 2 diabetes mellitus. World Journal of Diabetes. 2012;3(6):123–129 [7]. Brunzell JD, Davidson M, Furberg CD, et al. Lipoprotein management inpatients with cardiometabolic risk:consensus statement from the American diabetes association and the american college of cardiology [8]. foundation.Diabetes Care. 2008;31(4):811–822 [9]. Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the collaborative atorvastatin diabetes study (CARDS): multi centrer trial. The Lancet. 2004; 364(9435) :685–696. [10]. Shepherd J, Barter P, Carmena R, et al. Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the treating To new targets (TNT) study.Diabetes Care. 2006;29(6):1220–1226. [11]. American Diabetes Association.Standards of medical care in diabetes. Diabetes Care. 2009;32(supplement 1):S13–S61. [12]. Henry RR. Preventing cardiovascular complications of type 2 diabetes: focus on lipid management. Clinical Diabetes. [13]. Jones PH, Davidson MH, Stein EA, et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* trial) American Journal of Cardiology.2003;92(2):152–160. [14]. Group EUROASPIREIIS: Lifestyle and risk management and use of drug therapies in coronary patients from 15 countries. [15]. Principal results from EUROASPIRE II. Eur Heart J 2001,22:554-572. [16]. Schuster H, Barter PJ, Cheung RC, Bonnet J, Morrell JM, Watkins C, Kallend D, Raza A, for the MERCURY I Study Group: Effects ofswitching statins on achievement of lipid goals: MeasuringEffective Reductions in holesterol [17]. Using Rosuvastatin Therapy (MERCURY I) study. Am Heart J 2004,147:705-713. [18]. Pharmaceutical Management Agency. Prescription for pharmacoeconomic analysis: methods for cost-utility [19]. analysis. (8)